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Abstract
Objectives. The conclusive prognostic significance of cyclo-oxygenase-2 has been determined
in various cancers but not in nasopharyngeal carcinoma. Therefore, this study aimed to evalu-
ate the relationship of cyclo-oxygenase-2 expression with the survival outcome and treatment
response of nasopharyngeal carcinoma patients via a systematic meta-analysis approach.
Methods. A meta-analysis was conducted in compliance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (‘PRISMA’) checklist. The primary clinical char-
acteristics of patients, and hazard ratios with 95 per cent confidence intervals of overall sur-
vival data, were tabulated from eligible studies. The relationship of cyclo-oxygenase-2
expression with survival outcome (expressed as hazard ratio) and treatment response
(expressed as odds ratio) in nasopharyngeal carcinoma patients was analysed, and explained
with the aid of forest plot charts.
Results and conclusion. The pooled hazard ratio for overall survival was 2.02 (95 per cent
confidence interval = 1.65–2.47). This indicates that the over-expression of cyclo-oxygenase-
2 is significantly associated with the poor survival of nasopharyngeal carcinoma patients.
The pooled odds ratio of 0.98 (95 per cent confidence interval = 0.27–3.49) reveals that
over-expression of cyclo-oxygenase-2 was not significantly related to the treatment outcome.
Introduction
Nasopharyngeal carcinoma is a form of malignancy at the tissue of the upper section of
the pharynx behind the nose – the nasopharynx region.1 Globally, the disease accounts
for 65 000 deaths yearly and has a regionally varied incidence rate.2 In endemic regions,
such as Southern China, Southeast Asia and the Middle East, there are over 20 cases of
nasopharyngeal carcinoma per 100 000 people, although it is rare in North America
and Europe.3
Based on the World Health Organization classification, nasopharyngeal carcinoma is his-
tologically categorised into three subtypes: type I is characterised by keratinising differen-
tiated squamous cell carcinoma (SCC); type II (or 2a) is distinguished by non-keratinising
differentiated SCC; and type III (or 2b) is typified by non-keratinising undifferentiated basa-
loid SCC.4 The latter, more chemosensitive type III/2b is predominant among Asian cases,
whereas types I and II/2a are mostly found in Western countries.5
Risk factors for nasopharyngeal carcinoma include genetic factors, viral infection
(Epstein–Barr virus), environmental factors, lifestyle influences (smoking) and the con-
sumption of certain preserved foods.6 The early stages of malignancy usually involve inva-
sion of nasopharyngeal carcinoma cells to surrounding tissue and cervical lymph nodes.7,8
Despite the radio-sensitivity of nasopharyngeal carcinoma tumours, patients with
advanced disease stages show poor survival.9–12 Improved therapeutic techniques, such
as concurrent chemotherapy with or without neo-adjuvant or adjuvant intensity-
modulated radiotherapy (RT), and high-resolution magnetic resonance image monitor-
ing, have been the standard treatment protocol for locally advanced nasopharyngeal car-
cinoma.13–15 Nevertheless, relapse and metastasis still occur in approximately 20–50 per
cent of patients.16
Studies have shown that nasopharyngeal carcinoma patients with the same disease
classification present with different prognoses.17,18 This suggests that consideration of eth-
nicity19 and biomolecular factors associated with survival outcome20 may be necessary to
accurately distinguish nasopharyngeal carcinoma patients for individualised and tailored
treatment. Hence, it is important to identify prognostic factors (particularly molecular
and genetic factors) that correspond closely to the actual clinical outcomes for the
improvement of therapies, to yield a better treatment outcome.
One candidate biomarker of potential prognostic significance to nasopharyngeal car-
cinoma is the cyclo-oxygenase-2 gene. Expression of cyclo-oxygenase-2 has clinical and
prognostic significance in cancers of the head and neck.21 Its involvement in nasopharyn-
geal carcinoma carcinogenesis is most probably during the formation of the inflammatory
microenvironment associated with tumorigenesis and malignancy. Cyclo-oxygenase-2
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